Ardent Health, Inc. (ARDT)
(Delayed Data from NYSE)
$11.30 USD
+0.65 (6.10%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $11.30 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
A Value C Growth B Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ARDT 11.30 +0.65(6.10%)
Will ARDT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ARDT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ARDT
Ardent Health, Inc. (ARDT) Q2 Earnings and Revenues Surpass Estimates
Charles River Laboratories (CRL) Expected to Beat Earnings Estimates: Should You Buy?
ARDT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Bausch + Lomb (BLCO) Q2 Earnings and Revenues Surpass Estimates
Analysts Estimate Ardent Health, Inc. (ARDT) to Report a Decline in Earnings: What to Look Out for
Wall Street Analysts Predict a 36.55% Upside in Ardent Health Partners, Inc. (ARDT): Here's What You Should Know
Other News for ARDT
Decoding Ardent Health Inc (ARDT): A Strategic SWOT Insight
Q2 2025 Ardent Health Inc Earnings Call Transcript
ARDT Forecasts FY25 Revenue Growth
Ardent Health Partners Non-GAAP EPS of $0.52 beats by $0.20, revenue of $1.65B beats by $120M
Ardent Health (ARDT) Reports Strong Q2 Financial Performance